Pharma Eyes Riveted on JMA’s Stance on Off-Year Revision as New Chief Builds Ties with Govt

Kichiro Matsumoto, new president of the Japan Medical Association (JMA), is working to build relationships with the government and ruling parties. To wield its clout in the so-called “triple revision” in FY2024 and other issues it faces, the JMA will...read more